GILD|Analyst Targets
GILD|Company Info
GILD|Insider Trading
GILD|Fundamentals
GILD|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $2.19 | - | - |
| Q2'26 | $-7.38 | $-6.75 | +8.5% |
| Q1'26 | $1.95 | $2.03 | +4.0% |
| Q4'25 | $1.98 | $1.86 | -6.2% |
| Q3'25 | $2.14 | $2.47 | +15.7% |
| Q2'25 | $1.96 | $2.01 | +2.7% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $7.9B | - | - |
| Q2'26 | $7.5B | $7.8B | +3.4% |
| Q1'26 | $7.1B | $7.0B | -1.3% |
| Q4'25 | $6.9B | $7.9B | +14.1% |
| Q3'25 | - | $7.8B | - |
| Q2'25 | - | $7.1B | - |
GILD|Monthly Returns
Market Data
GILD Stock Snapshot
- Market cap
- 184.77B
- P/E ratio
- 21.7
- Day range
- $147.48 – $153.76
- News sentiment
- 41/100 · Neutral
- Analyst target
- $159.62 (+3.9%)
- Consensus
- Buy · 39 analysts
GILD is trading with the trend behind it, which is what pushes the technical read bullish. Sector peers are worth watching - large caps in Healthcare tend to move together on rotation.
Reverse DCF
What growth is priced into GILD?
At today's price, Gilead Sciences, Inc. needs to grow free cash flow about 4.4% a year for the next 10 years to justify its valuation at a 7.74% cost of capital. Over its actual history it has compounded free cash flow at 9.8% a year, so the market is asking for 5.4 percentage points below its own delivered rate. On that basis GILD looks priced below what its own growth record supports.
- Implied FCF growth
- 4.4%
- Historical FCF CAGR
- 9.8%
- Growth gap
- -5.4 pts
- Verdict
- CHEAP
- Discount rate (WACC)
- 7.74%
- Beta
- 0.61
Behaviour On Record
What GILD's own history says about today's numbers
- Realized volatility (21d)
- 20.0% 33rd pct
- Below its peak
- -5.2%
- vs 200-day average
- +7.4%
- Up days (1y)
- 48%
Gilead Sciences, Inc. is currently running 20.0% annualised volatility over the last 21 sessions. Measured against GILD's own 13 years of daily returns rather than a market-wide average, that is the 33rd percentile — on the quiet side for this stock, against a typical reading of 22.6%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.
GILD is trading -5.2% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -21.4%, and the deepest was -36.5% in 2020. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.
Price sits +7.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 70th percentile — a somewhat wider gap than its own norm. Over the past year GILD closed higher on 48% of sessions, and it is currently 3 sessions into a falling streak.
On October specifically: over 14 years of records, GILD finished the month higher 9 of 14 times, with a median return of +3.1% and an average of +2.2%. Its strongest month historically has been January at +3.3% on average, its weakest December at -2.4%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.
Overnight risk is measurable too: GILD has opened more than 2% away from the prior close in 30 of 3,268 sessions (0.9% of the time), with the largest gaps running +3.3% and -5.6%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.
Across the last 3 dated reports on file, GILD moved an average of 3.1% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.7% and a largest of +7.2%.
All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-14, split-adjusted, recomputed daily. Percentiles are against GILD's own 13-year history, not a peer group or index.
Sector Rotation
Is money rotating into or out of GILD's sector?
Gilead Sciences, Inc. sits in the Health Care sector, currently ranked 2nd of 12 GICS sectors by relative-strength rotation score (leading).
- Sector rank
- #2 of 12
- Sector state
- Leading
- Sector rotation score
- 91
Analyst Rating Changes
Are analysts turning bullish or bearish on GILD?
RBC Capital most recently reiterated its rating on Gilead Sciences, Inc. to Sector Perform on Oct 8, 2026 with a price target of $126 (from $123). Over the last 90 days, coverage has run 0 upgrades against 1 downgrade, a net bearish lean.
- Latest action
- RBC Capital — Sector Perform
- 90-day upgrades
- 0
- 90-day downgrades
- 1
- Net rating momentum
- -1
Peers & ETF holders
GILD peers & ETF holders
Drug Manufacturers - GeneralMarket cap · today
News Sentiment Analysis
Sentiment gathered from recent headlines
Recent News Coverage
Most recent articles, ranked by recency (click to expand).
Technical Analysis
Real-time indicators across multiple timeframes
| Manager | Trend | Shares Held | % of Co. | Position Value | Filed |
|---|---|---|---|---|---|
| BlackRock, Inc. | ▲ Buy | 121,844,108 | 9.74% | $15.39B | 2026-08-07 |
| Vanguard Group Inc | ▲ Buy | 121,097,336 | 9.68% | $14.86B | 2026-01-29 |
| FMR LLC (Fidelity) | ▼ Sell | 66,870,816 | 5.35% | $8.45B | 2026-08-13 |
| Capital World Investors | ▼ Sell | 40,988,975 | 3.28% | $5.18B | 2026-08-12 |
| Invesco Ltd. | ▲ Buy | 39,819,151 | 3.18% | $5.03B | 2026-08-14 |
| Geode Capital Management, LLC | ▲ Buy | 30,065,642 | 2.40% | $3.80B | 2026-08-12 |
| Morgan Stanley | ▲ Buy | 24,004,354 | 1.92% | $3.03B | 2026-08-13 |
| Norges Bank | ▲ Buy | 21,965,555 | 1.76% | $2.78B | 2026-08-12 |
| JPMorgan Chase & Co | ▼ Sell | 20,820,621 | 1.66% | $2.63B | 2026-08-12 |
| Capital Research Global Investors | ▼ Sell | 19,393,296 | 1.55% | $2.45B | 2026-08-12 |
| Bank of America Corp | ▼ Sell | 18,649,065 | 1.49% | $2.36B | 2026-08-14 |
| Northern Trust Corp | ▲ Buy | 13,828,010 | 1.11% | $1.75B | 2026-08-13 |
| Wellington Management Group LLP | ▼ Sell | 12,699,683 | 1.02% | $1.60B | 2026-08-14 |
| Goldman Sachs Group Inc | ▼ Sell | 10,778,294 | 0.86% | $1.36B | 2026-08-14 |
| Wells Fargo & Company | ▼ Sell | 6,439,586 | 0.51% | $813.58M | 2026-08-14 |
| AllianceBernstein L.P. | ▼ Sell | 4,613,383 | 0.37% | $642.97M | 2026-08-14 |
| Citadel Advisors LLC | ▼ Sell | 3,480,444 | 0.28% | $439.72M | 2026-09-02 |
| Citigroup Inc | ▲ Buy | 2,969,159 | 0.24% | $375.12M | 2026-08-03 |
| D. E. Shaw & Co., Inc. | ▲ Buy | 2,294,789 | 0.18% | $289.92M | 2026-08-14 |
| Renaissance Technologies LLC | ▲ Buy | 2,217,376 | 0.18% | $280.14M | 2026-08-13 |
| Janus Henderson Group plc | ▲ Buy | 1,972,639 | 0.16% | $274.92M | 2026-05-18 |
| Squarepoint Ops LLC | ▲ Buy | 1,823,224 | 0.15% | $230.35M | 2026-08-14 |
| Prudential Financial Inc | ▲ Buy | 1,759,349 | 0.14% | $222.28M | 2026-08-12 |
| Millennium Management LLC | ▲ Buy | 1,458,924 | 0.12% | $184.32M | 2026-08-14 |
| Point72 Asset Management, L.P. | ▲ Buy | 1,437,685 | 0.11% | $181.64M | 2026-08-14 |
| Member | Chamber | State | Type | Amount | Traded | Filed |
|---|---|---|---|---|---|---|
| Jared Moskowitz | House | FL23 | ▲ Buy | $1K - $15K | 2026-05-06 | 2026-06-19 |
| Alan Armstrong | Senate | OK | ▲ Buy | $1K - $15K | 2026-03-27 | 2026-07-21 |
| Josh Gottheimer | House | NJ05 | ▲ Buy | $1K - $15K | 2026-01-27 | 2026-02-26 |
| Valerie Hoyle | House | OR04 | ▼ Sell | $1K - $15K | 2025-09-23 | 2025-10-10 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-06-06 | 2025-06-18 |
| Josh Gottheimer | House | NJ05 | ▼ Sell | $1K - $15K | 2025-05-14 | 2025-06-11 |
| Jefferson Shreve | House | IN06 | ▼ Sell | $15K - $50K | 2025-05-12 | 2025-06-22 |
| Marjorie Taylor Greene | House | GA14 | ▲ Buy | $1K - $15K | 2025-05-05 | 2025-05-06 |
| John Boozman | Senate | AR | ▼ Sell | $1K - $15K | 2025-04-16 | 2025-05-14 |
| Jefferson Shreve | House | IN06 | ▲ Buy | $15K - $50K | 2025-03-31 | 2025-04-11 |
| Carol Devine Miller | House | WV01 | ▲ Buy | $1K - $15K | 2025-03-10 | 2025-04-11 |
| Josh Gottheimer | House | NJ05 | ▲ Buy | $1K - $15K | 2025-03-07 | 2025-04-10 |
| Valerie Hoyle | House | OR04 | ▲ Buy | $1K - $15K | 2024-10-29 | 2025-09-12 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2024-05-10 | 2026-08-05 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-05-08 | 2026-08-05 |
| Tommy Tuberville | Senate | AL | ▲ Buy | $1K - $15K | 2024-04-05 | 2024-05-15 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2024-04-03 | 2024-05-15 |
| Tommy Tuberville | Senate | AL | ▼ Sell | $1K - $15K | 2022-01-13 | 2022-02-14 |
| Jerry Moran | Senate | - | ▼ Sell | $1K - $15K | 2021-12-21 | 2022-01-21 |
| Jerry Moran | Senate | - | ▲ Buy | $1K - $15K | 2020-08-21 | 2020-09-08 |
| Jerry Moran | Senate | - | ▲ Buy | $1K - $15K | 2019-09-25 | 2020-08-05 |
| Shelley Moore Capito | Senate | WV | ▼ Sell | $1K - $15K | 2019-03-11 | 2019-04-17 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $1K - $15K | 2018-09-25 | 2018-10-18 |
| Angus King | Senate | - | ▼ Sell | $1K - $15K | 2018-04-23 | 2018-05-22 |
| Shelley Moore Capito | Senate | WV | ▲ Buy | $1K - $15K | 2017-10-25 | 2017-11-07 |